People & Business :: M&A
Glaxo and Novartis announce major three-part business transaction
12:27 PM MDT | April 22, 2014 | Natasha Alperowicz
GlaxoSmithKline (GSK) today announced a major, three-part transaction with Novartis involving its consumer health-care, vaccines, and oncology businesses. GSK and Novartis, as part of the transaction, will create a new, world-leading consumer health-care business with 2013 pro forma revenues of £6.5 billion ($10.9 billion). GSK will have a 63.5% equity interest in the joint venture. Meanwhile, GSK will acquire Novartis’s global vaccines business, excluding influenza vaccines, for an initial cash consideration of $5.25 billion and subsequent potential...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee